Key statistics
On Thursday, Tevogen Bio Holdings Inc (G28:FRA) closed at 0.382, 8.52% above its 52-week low of 0.352, set on Sep 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.362 |
---|---|
High | 0.382 |
Low | 0.362 |
Bid | -- |
Offer | -- |
Previous close | 0.382 |
Average volume | 100.00 |
---|---|
Shares outstanding | 170.65m |
Free float | 10.19m |
P/E (TTM) | 1.15 |
Market cap | 73.82m USD |
EPS (TTM) | 0.3758 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 14:29 BST.
More ▼
Announcements
- Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
- CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
- Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health
- Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
- Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
- Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
- Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility
- Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
- Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
- Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
More ▼